Analysts Expect Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Will Announce Earnings of -$0.73 Per Share

Analysts expect that Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPIGet Rating) will post ($0.73) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Checkmate Pharmaceuticals’ earnings. Checkmate Pharmaceuticals reported earnings per share of ($0.65) during the same quarter last year, which would suggest a negative year-over-year growth rate of 12.3%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Checkmate Pharmaceuticals will report full-year earnings of ($3.15) per share for the current fiscal year, with EPS estimates ranging from ($3.24) to ($3.05). For the next financial year, analysts expect that the company will post earnings of ($2.83) per share, with EPS estimates ranging from ($4.11) to ($1.55). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Checkmate Pharmaceuticals.

Checkmate Pharmaceuticals (NASDAQ:CMPIGet Rating) last issued its quarterly earnings data on Tuesday, March 29th. The company reported ($0.62) earnings per share for the quarter.

CMPI has been the topic of several recent research reports. BTIG Research lowered shares of Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, April 20th. Zacks Investment Research raised shares of Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, April 21st.

In other news, major shareholder Global Strategic Fund I. Venbio sold 69,230 shares of the firm’s stock in a transaction on Friday, April 29th. The shares were sold at an average price of $10.38, for a total value of $718,607.40. Following the sale, the insider now owns 2,805,833 shares in the company, valued at $29,124,546.54. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Global Strategic Fund I. Venbio sold 47,396 shares of the firm’s stock in a transaction on Wednesday, April 27th. The stock was sold at an average price of $10.38, for a total transaction of $491,970.48. Following the completion of the sale, the insider now owns 2,948,463 shares in the company, valued at approximately $30,605,045.94. The disclosure for this sale can be found here. In the last three months, insiders sold 608,537 shares of company stock worth $6,316,970. Insiders own 6.30% of the company’s stock.

A hedge fund recently bought a new stake in Checkmate Pharmaceuticals stock. Millennium Management LLC purchased a new stake in Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPIGet Rating) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 10,633 shares of the company’s stock, valued at approximately $31,000. 74.56% of the stock is owned by hedge funds and other institutional investors.

Shares of CMPI opened at $10.38 on Friday. The firm’s 50 day moving average price is $4.37 and its 200 day moving average price is $3.66. Checkmate Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $10.48.

Checkmate Pharmaceuticals Company Profile (Get Rating)

Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.

Read More

Get a free copy of the Zacks research report on Checkmate Pharmaceuticals (CMPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Checkmate Pharmaceuticals (NASDAQ:CMPI)

Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.